PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

The increasing incidence of sexually transmitted bacterial infections (STIs) is a major public health problem worldwide.

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

The Associated Press Condoms and other sexual wellness items are made available to students at the University of Mississippi ...

1 The phase 3 PURPOSE 2 trial is assessing lenacapavir as a pre-exposure prophylaxis (PrEP) medicine to reduce the chance of getting HIV through sex, comparing it when taken twice per year as PrEP ...

HIV prevention data will include an analysis of newly initiated pre-exposure prophylaxis (PrEP) use in priority populations with unmet needs for PrEP in the U.S. Additional HIV research findings ...

A health worker takes blood samples of people who want to undertake voluntary HIV testing at the University of the Philippines Manila. Jonathan Cellona, ABS-CBN News/FileMANILA — The Philippines ...

Chaphalkar, PhD.New research reveals that doxycycline post-exposure prophylaxis raises resistance gene levels in the gut, but ...

After launching its “Plan First!” program just over a year ago, the Michigan Department of Health and Human Services says the ...

About Apretude (cabotegravir LA for PrEP) Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at ...

Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...